Jak-2 positive myeloproliferative neoplasms

Current Treatment Options in Oncology

Volumn 15, Issue 2, 2014, Pages 147-156

  Muxí, Pablo J ^a   Oliver, Ana Carolina ^a  

^a British Hospital Montevideo   (Uruguay)

Author keywords

Chronic myelogenous meukemia (CML); Chronic neutrophilic leukemia (CNL); Essential thromobocythemia; JAK2; JAK2 inhibitors; Myeloproliferative neoplasms; Polycythemia vera (PV); Primary myelofibrosis (PMF); Ruxolitinib

Indexed keywords

BCR ABL PROTEIN; FEDRATINIB; GANDOTINIB; JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; MOMELOTINIB; PACRITINIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; RUXOLITINIB; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; JAK2 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TARGETING; GENETIC ASSOCIATION; HUMAN; MOLECULARLY TARGETED THERAPY; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NONHUMAN; PHILADELPHIA 1 CHROMOSOME; POINT MUTATION; POLYCYTHEMIA VERA; QUALITY OF LIFE; SIGNAL TRANSDUCTION; SPLEEN SIZE; SPLENOMEGALY; THROMBOCYTHEMIA; THROMBOCYTOPENIA; CELL PROLIFERATION; CHRONIC NEUTROPHILIC LEUKEMIA; GENETICS; METABOLISM; MUTATION; MYELOPROLIFERATIVE DISORDER; PROGNOSIS;

ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; ENZYME INHIBITORS; HUMANS; JANUS KINASE 2; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, NEUTROPHILIC, CHRONIC; MUTATION; MYELOPROLIFERATIVE DISORDERS; PHILADELPHIA CHROMOSOME; POLYCYTHEMIA VERA; PRIMARY MYELOFIBROSIS; PROGNOSIS; PYRAZOLES; SIGNAL TRANSDUCTION; THROMBOCYTHEMIA, ESSENTIAL;

EID: 84902370811     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-014-0279-3     Document Type: Article

References (63)

1. Dameshek W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372-5.
2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. 4th ed. Lyon: WHO Press; 2008.
3. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. Cancer statistics. Cancer J Clin. 2004;54:8-29.
4. Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocytemia. Semin Thromb Hemost. 2006;32:171-3.
5. Johansson P, Kutti J, Andreasson B, Safai-Kutti S, Vilen L, Wedel H, et al. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983-99. J Intern Med. 2004;256:161-5. (Pubitemid 38998263)
6. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. Cancer. 2007;109:68.
7. .• Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118:401. This study validates the QOL assessment form in MPN.
8. Emanuel RM, Dueck AC, Geyer HL, Kiladjian JJ, Slot S, Zweegman S, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30:4098.
9. .• Tefferi A, Cervantes F, Mesa R, Passamonti F, Verstovsek S, Vannucchi AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122:1395-8. This study revises response criteria in MPN.
10. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;142:1497.
11. Rowley JD. Letter. A new consistent abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-3.
12. Bartram C, Klein A, Hagemeijer A, Agthoven T, Geurts van Kessel A, Bootsma D, et al. Translocation of c-abl oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukemia. Nature. 1983;306:277-80. (Pubitemid 14232360)
13. Groffen J, Stephenson JR, Heisterkamp N, Klein A, Bartram C, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, BCR, on chromosome 22. Cell. 1984;36:93-9. (Pubitemid 14155374)
14. Quintas Cardama A, Kantarjian H, Cortes J. Molecular biology and cytogenetics of chronic myeloid leukemia. Neoplastic Diseases of the Blood. 5th Ed. Springer. 2012;91-102.
15. Daley GQ, Van Etten RA, Baltimora D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990;247:824-30.
16. Druker B, Tamura S, Buchdunger E, Ohno S, Bagby G, Lydon N. Preclinical evaluation of a selective inhibitor of the ABL tyrosine kinase as a therapeutic agent for chronic myelogenous leukemia. ASH Annual Meeting Abstracts. Blood. 1995;601a. [Abstract 2392].
17. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. For the International STI571 CML study group. N Engl J Med. 2002;346:645-54.
18. O'Brien S, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004. (Pubitemid 36302244)
19. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003;349:1423-32. (Pubitemid 37211057)
20. Vainshenker W, Constantinescu SN. A unique activation mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases. Hematology Am Soc Hematol Educ Program. Education Book January 1, vol 2005;2005;195-200.
21. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature. 2005;434:1144-8. (Pubitemid 40663494)
22. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-90. (Pubitemid 40570926)
23. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-97. (Pubitemid 40544655)
24. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-61. (Pubitemid 40386783)
25. Neubauer H, Cumano A, Müller M, Wu H, Huffstadt U, Pfeffer K. JAK2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 1998;93:397-409. (Pubitemid 28232084)
26. Parganas E, Wang D, Stravopodis D, Topham DJ, Marine JC, Teglund S, et al. JAK2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93:385 -95.
27. Staerk J, Constantinescu S. The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective. JAK-STAT. 2012;1:184-90.
28. Garcon L, Rivat C, James C, Lacout C, Camara-Clayette V, Ugo V, et al. Constitutive activation of STAT5 and BCL-xL overexpression can induce endogenous erythroid colony formation in human primary cells. Blood. 2006;108:1551-4. (Pubitemid 44316120)
29. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162-8. (Pubitemid 41291734)
30. Vizmanos JL, Ormazabal C, Larrayoz MJ, Cross NC, Calasanz MJ. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients. Leukemia. 2006;20:534-5. (Pubitemid 43291762)
31. Ceesay M, Lea N, Ingram W, Westwood N, Gaken J, Mohamedali A, et al. The JAK2 V617Fmutation is rare in RARS but common in RARS-T. Leukemia. 2006;20:2060-1. (Pubitemid 44614905)
32. Levine R, Loriaux M, Huntly B, Loh M, Beran M, Stoffregen E, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005;106:3377-9. (Pubitemid 41609169)
33. Stijnis C, Kroes W, Balkassmi S, Marijt E, van Rossum A, Bakker E, et al. No evidence for JAK2(V617F) mutation in monoclonal B cells in 2 patients with polycythemia vera and concurrent monoclonal B cell disorder. Acta Haematol. 2012;128:183-6.
34. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459-68. (Pubitemid 46193073)
35. Wang JY, Ai XF, Xu JQ, Li QH, Xu ZF, Qin TJ, et al. JAK2 exon 12 mutations in patients with Philadelphia (Ph) chromosome-negative myeloproliferative neoplasms. Zhonghua Xue Ye Xue Za Zhi. 2012;33:705-9.
36. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472-6.
37. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3:e270.
38. Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, et al. Ratio of mutant JAK2-V617Fto wild-type JAK2 determines the MPD phenotypesin transgenic mice. Blood. 2008;111:3931-40.
39. Vannucchi A, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008;22:1299-307.
40. Austin SK, Lambert JR. The JAK2V617F mutation and thrombosis. Br J Haematol. 2008;143:307-20.
41. Alvarez-Larrán A, Bellosillo B, Martínez-Avilés L, Saumell S, Salar A, Abella E, et al. Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients. Br J Haematol. 2009;146:504-9.
42. Vannucchi AM, Antonioli E, Guglielmelli P, Rambaldi A, Barosi G, Marchioli R, et al. Clinical profile of homozygous JAK2 617V9 F mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2007;110:840-6. (Pubitemid 47267419)
43. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, et al. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood. 2005;105:2664-70. (Pubitemid 40446255)
44. Kreft A, Büche G, Ghalibafian M, Buhr T, Fischer T, Kirkpatrick CJ. The incidence of myelofibrosis in essential thrombocythaemia, polycythemia vera and chronic idiopathic myelofibrosis: a retrospective evaluation of sequential bone marrow biopsies. Acta Haematol. 2005;113:137-43. (Pubitemid 40522818)
45. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000;342:1255-65. (Pubitemid 30235956)
46. Cross N. Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematol Am Soc Hematol Educ Prog. 2011;2011:208-14.
47. Klidajian JL. New approaches to therapy for myeloproliferative neoplasms. Hematol Educ. 2012;6:279-84.
48. .•• Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis N Engl J Med. 2010;363:1117-27. Analysis of safety and efficacy of ruxolitinib in MF.
49. .•• Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366:799-807. Phase III study for ruxolitinib in MF.
50. .•• Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib vs best available therapy for myelofibrosis. N Engl J Med. 2012;366:787-98. Phase III study for ruxolitinib in MF.
51. .• Mesa RA, Gotlib J, Gupta V, Catalano JV, Deininger MW, Shields AL, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2013;31:1285-92. This study reports impact of ruxolitinib in QOL.
52. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, Dipersio JF, et al. Efficacy, safety and survival with ruxolitinib treatment in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Blood. 2013;122(25):4047-4053.
53. Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a Phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Haematol. 1 2013;98(12):1865-1871.
54. Harrison CN, Mesa RA, Kiladjian JJ, Al-Ali HK, Gisslinger H, Knoops L, et al. Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib vs best available therapy. Br J Haematol. 2013;162:229-39.
55. Kvasnicka HM, Thiele J, Bueso-Ramos CE, Hou K, Cortes JE, Kantarjian HM, et al. Exploratory analysis of the effect of ruxolitinib on bone marrow morphology in patients with myelofibrosis. ASCO Annual Meeting Abstracts. J Clin Oncol. 2013;31(Suppl):7030.
56. Vannucchi A, Kiladjian JJ, Gisslinger H, Passamonti F, Al-Ali HK, Sirulnik LA, et al. Reductions in JAK2V617F allele burden with ruxolitinib treatment in COMFORT-II, a Phase III study comparing the safety and efficacy of ruxolitinib to best available therapy (BAT). J Clin Oncol. 2012;30(Suppl). [Abstract 6514].
57. Verstovsek S, Passamonti P, Rambaldi A, Giovanni Barosi G, Peter J, Rosen PJ, et al. Long-term efficacy and safety results from a Phase II study of ruxolitinib in patients with polycythemia vera. ASH Annual Meeting Abstracts. Blood. 2012;120:804.
58. Talpaz M, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, Liu F, et al. A Phase II randomized dose-ranging study of the JAK2-selective inhibitor sar302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera (PV), MF, or post-essential thrombocythemia (ET)MF. ASH Annual Meeting Abstracts. Blood. 2012;120. [Abstract 2837].
59. Pardanani A, Gotlib J, Jamieson C, Cortes JE, Talpaz M., Stone R, et al. SAR302503: interim safety, efficacy and long-term impact on JAK2 V617F allele burden in a Phase I/II study in patients with myelofibrosis. ASH Annual Meeting Abstracts. Blood. 2011;118. [Abstract 3838].
60. Deeg HJ, Odenike O, Scott BL, Estrov Z, Cortes JE, Thomas DA, et al. Phase II study of SB1518, an orally available novel JAK2 inhibitor, in patients with myelofibrosis. J Clin Oncol. 2011;29(Suppl)Abstract 6515].
61. Pardanani A, Gotlib J, Gupta V, Roberts AW, Wadleigh M, Sirhan S, et al. An expanded multicenter Phase I/II study of CYT387, a JAK- 1/2 inhibitor for the treatment of myelofibrosis. ASH Annual Meeting Abstracts. Blood. 2011;118. [Abstract 3849].
62. Pardanani AD, Caramazza D, George G, Lasho TL, Hogan WJ, Litzow MR, et al. Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis. J Clin Oncol. 29:2011(Suppl). [Abstract 6514].
63. Verstovsek S, Mesa RA, Kloeker-Rhoades S, Giles JL, Pitou C, Jones E, et al. Phase I study of the JAK2 V617F Inhibitor, LY2784544, in patients with myelofibrosis (MF), polycythemia Vera (PV), and essential thrombocythemia (ET). ASH Annual Meeting Abstracts. Blood. 2011;118. [Abstract 2814].